Skip to main content

02.03.2024 | Review

European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges

verfasst von: Angela Pirillo, Lale Tokgözoğlu, Alberico L. Catapano

Erschienen in: Current Atherosclerosis Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Genetic, experimental, epidemiologic, and clinical data support the causal role of elevated levels of low-density lipoprotein cholesterol (LDL-C) in atherosclerosis and cardiovascular disease (CVD). The recommendations of the 2019 European guidelines are based on the concept of differential CV risk, which in turn defines the LDL-C goals that should be achieved.

Recent Findings

The 2019 ESC/EAS guidelines for dyslipidaemia use the Systematic COronary Risk Evaluation (SCORE) model to assess CV risk, which provides a 10-year risk of fatal CV event. The SCORE model has recently been updated to reflect current rates of cardiovascular disease in Europe. The new SCORE2 model provides estimates of the 10-year risk of fatal and non-fatal CVD events in people aged 40–69 years, thus improving the identification of individuals at higher risk of a CVD event. However, as in the SCORE age is the main determinant of risk, young people have a relatively low estimated 10-year risk of a CV event even with high levels of one or more causal risk factors. Individuals with familial hypercholesterolaemia, who have elevated LDL-C levels from birth and have a high risk of premature CVD, are one example. The concept of cumulative LDL exposure is thus becoming increasingly important. This is also supported by Mendelian randomisation studies showing that carrying genetic variants associated with lower LDL-C levels reduces CV risk.

Summary

These observations have introduced the concept of “cholesterol-years”, which takes into account both LDL-C levels and time of exposure. It is crucial that future European guidelines pay more attention to this point.
Literatur
4.
Zurück zum Zitat Catapano AL, Graham I, De Backer G, et al: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016, 37(39):2999-3058. /10.1093/eurheartj/ehw272 Catapano AL, Graham I, De Backer G, et al: 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016, 37(39):2999-3058. /10.1093/eurheartj/ehw272
7.••
Zurück zum Zitat SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54. https://doi.org/10.1093/eurheartj/ehab309. This paper describes the new algorithm for predicting the 10-year risk of fatal and non-fatal CVD in European populations, which aims to improve the identification of individuals at higher risk of CVD.CrossRef SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54. https://​doi.​org/​10.​1093/​eurheartj/​ehab309. This paper describes the new algorithm for predicting the 10-year risk of fatal and non-fatal CVD in European populations, which aims to improve the identification of individuals at higher risk of CVD.CrossRef
13.••
Zurück zum Zitat Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507–16. https://doi.org/10.1016/j.jacc.2020.07.059. This paper shows that the risk of a future CVD event at a given age increases with the total accumulated area under the LDL-C curve as a function of age and that it is modulated by the time course of area accumulation.CrossRefPubMed Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507–16. https://​doi.​org/​10.​1016/​j.​jacc.​2020.​07.​059. This paper shows that the risk of a future CVD event at a given age increases with the total accumulated area under the LDL-C curve as a function of age and that it is modulated by the time course of area accumulation.CrossRefPubMed
Metadaten
Titel
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges
verfasst von
Angela Pirillo
Lale Tokgözoğlu
Alberico L. Catapano
Publikationsdatum
02.03.2024
Verlag
Springer US
Erschienen in
Current Atherosclerosis Reports
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-024-01194-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.